NasdaqGS:AMRXPharmaceuticals
Amneal Pharmaceuticals (AMRX) Wins FDA Nod For Iohexol, Is The Upside Already Priced In?
Amneal Pharmaceuticals (AMRX) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for additional strengths and vial sizes of its iohexol injection, which expands its radiographic contrast agent offering.
See our latest analysis for Amneal Pharmaceuticals.
The FDA approval arrives at a time when Amneal Pharmaceuticals’ share price momentum is strong, with a 30 day share price return of 10.47% and a year to date share price return of 50.87%, alongside a 1 year...